{"task_id": "4e268b22c0d5d1d0", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 240/464)", "text": "uired\nChemotherapy-Induced Nausea and Vomiting\n229\n\n--- Page 251 ---\nRelated Topic\nNausea and Vomiting (p. 111)\nEMETOGENIC LEVELS OF INTRAVENOUSLY\nADMINISTERED ANTINEOPLASTIC AGENTS\nHIGH RISK (>90%)\ncarmustine, cisplatin, cyclopho\nsphamide (>1.5 g/m2), dacarbazine, mechloretha\nmine, streptozocin\nMODERATE RISK (31 90%)\ncarboplatin, cyclopho\nsphamide\n(\u00051.5\ng/m2),\ncytarabine\n(>1 g/m2),\ndaunorubicin, doxorubicin, epirubicin, idarubicin,\nifosfamide, irinotecan, oxaliplatin\nLOW RISK (10 30%)\nbortezomib, cetuximab, cytar\nabine (\u00051 g/m2), docetaxel, etoposide, fluorouracil,\ngemcitabine, ixabepilone, lapatinib, methotrexate,\nmitomycin, mitoxantrone, paclitaxel, pemetrexed,\ntopotecan, temsirolimus, trastuzumab\nMINIMAL RISK (<10% risk of CINV in the absence of\nantiemetic prophylaxis)\nbevacizumab, bleomycin,\nbusulfan, cladribine, fludarabine, vinblastine, vincris\ntine, vinorelbine\nMANAGEMENT\nPREVENTION IS KEY\nANTICIPATORY NAUSEA AND VOMITING ( 3 to\n4 h)\nconsider use of distraction and benzodiazepines\nACUTE NAUSEA AND VOMITING (0\n24 h)\n5HT3\nantagonists and steroids are key. NK1 antagonists\nmay be added for patients on highly emetogenic\nchemotherapy\nDELAYED NAUSEA AND VOMITING (>24 h)\nasso\nciated with cisplatin, cyclophosphamide, ifosfamide\nat higher doses and doxorubicin. NK1 antagonists,\n5HT3 antagonists, and steroids are all effective\nCHRONIC NAUSEA AND VOMITING\nunlikely to be\ndue to chemotherapy alone. Multi factorial interven\ntions required. Avoid long term use of 5HT3/NK1\nantagonists\nMANAGEMENT (CONT\u2019D)\nTREATMENT OVERVIEW FOR PREVENTING\nACUTE AND DELAYED CINV\nRisk\nNK1\nantagonist\n5HT3\nantagonist\nSteroid Etca\nHighb\nX\nX\nX\nX\nModerate\nX\nX\nX\nLow\nX\nX\nMinimal\nX\nachoices include metoclopramide 10 mg PO q4h\nPRN and prochlorperazine 10 mg PO q4h PRN\nbhighly emetogenic chemotherapy or doxorubicin/\ncyclophosphamide (AC) combination chemotherapy\nTREATMENT ISSUES\nHIGH RISK CHEMOTHERAPY OR AC COMBINATION\nCHEMOTHERAPY\naprepitant 125 mg PO on day 1,\nthen 80 mg PO days 2 3, PLUS ondansetron 8 12 mg IV\nor 16 24 mg PO on day 1, PLUS dexamethasone 12 mg\nPO/IV on day 1, then 8 mg PO days 2 4 PLUS metoclo\npramide 10 mg PO q4h PRN or prochlorperazine 10 mg\nPO q4h PRN\nMODERATE RISK CHEMOTHERAPY\nondansetron\n8 mg IV or 8 mg PO BID on day 1, then 8 mg PO\nBID on days 2 3, PLUS dexamethasone 12 mg PO/IV\non day 1, then 8 mg PO or 4 mg PO BID days 2 3 PLUS\nmetoclopramide 10 mg PO q4h PRN or prochlorpera\nzine 10 mg PO q4h PRN\nLOW RISK CHEMOTHERAPY\ndexamethasone 8 mg\nPO/IV day 1 PLUS metoclopramide 10 mg PO q4h PRN\nor prochlorperazine 10 mg PO q4h PRN\nLOW,\nRISK\nCHEMOTHERAPY\nmetoclopramide\n10 mg PO q4h PRN or prochlorperazine 10 mg PO\nq4h PRN\nNOTE\nfor patients with significant nausea and\nvomiting despite proper oral antiemetic use, consider\nadmission for intravenous hydration and medication\nadministration\nOral Mucositis\nPATHOPHYSIOLOGY\nRISK FACTORS FOR ORAL MUCOSITIS\n\u0002\nPERSONAL\nyounger age, poor oral hygiene, smok\ning, alcohol use\n\u0002\nCHEMOTHERAPY\nbleomycin, capecitabine, chlor\nambucil, cytarabine, doxorubicin, etoposide, meth\notrexate, vinblastine, 5 fluorouracil\n\u0002\nTARGETED AGENTS\nRAD001\n\u0002\nRADIATION\nhead and neck region\nCOMPLICATIONS OF ORAL MUCOSITIS\nsevere\npain, bleeding, superinfections (bacteremia, febrile\nneutropenia)\nNCI CTC GRADING V4.0\nGrade\nOral mucositis\n1\nAsymptomatic or mild symptoms;\nintervention not indicated\n2\nModerate pain; not interfering with oral\nintake; modified diet indicated\n3\nSevere pain; interfering with oral intake\n4\nLife threatening consequences; urgent\nintervention indicated\n230\nOral Mucositis", "text_length": 3540, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 240/464)", "type": "chunk", "chunk_index": 239, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.577029", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.577845", "status": "complete", "chunks_added": 2}